铂族金属抗肿瘤药物顺铂和卡铂已广泛应用于临床,它们对治疗睾丸肿瘤、卵巢癌和肺癌等十几种肿瘤有显著的疗效.近年来又有奈达铂、草酸铂和乐铂等获批准进入临床应用.但目前这些临床应用的铂族金属抗肿瘤药口服活性低,都是静脉途径给药.本文介绍了已进入III期临床试验的第一个口服活性铂抗肿瘤药物赛特铂及其合成、化学特点、临床前和临床研究情况.
参考文献
| [1] | Ernest W;Chhristen M G .Current status of platinum-based antitumor drugs[J].Chemical Reviews,1999,99:2451-2466. |
| [2] | 杨一昆,普绍平,高文桂.顺铂的应用及铂族金属抗癌药物的研究进展[J].中国新药杂志,1999(12):797-800. |
| [3] | Karren Ferrante;Benjamine Winograd;Renzo Canetta .Promising new developments in cancer chemotherapy[J].Cancer Chemotherapy and Pharmacology,1999(43):61-68. |
| [4] | Giandomenico CM.;Murrer BA.;Vollano JF.;Rheinheimer MI. Wyer SB.;Bossard GE.;Higgins JD.;Abrams MJ. .CARBOXYLATION OF KINETICALLY INERT PLATINUM(IV) HYDROXY COMPLEXES - AN ENTREE INTO ORALLY ACTIVE PLATINUM(IV) ANTITUMOR AGENTS[J].Inorganic Chemistry: A Research Journal that Includes Bioinorganic, Catalytic, Organometallic, Solid-State, and Synthetic Chemistry and Reaction Dynamics,1995(5):1015-1021. |
| [5] | Lloyd R Kelland.The development of orally active platinum drugs[A].Zurich:Verl Helvetica Chimica Acta, Weinheim:Wiley-VCH,1999:497-521. |
| [6] | Neidle S;Snook C F;Murrer B A et al.Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV),an orally active antitumour drug[J].ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS,1995(51):822-824. |
| [7] | HARRAP K R;Murrer B A;Abrame M J.Ammine/amine Platinum IV Dicarboxylates: a Novel Class of Complexes which Circumvent Intrinsic Cisplatin Resistance,Platinum and other Metal Coordination in Cancer Chemotherapy[M].New York: S B Howell Plenum Press New York,1991:391-400. |
| [8] | Kelland L R;George Abel;Mckeage M J et al.Preclinical antitumor evaluation of bis-acctato dichloro-cyclohexyle amine platinum(IV):an orally active platinum drug[J].Cancer Research,1993(53):2581-2586. |
| [9] | Mckeage M J;Boxall F E;Mervyn Jones et al.Lack of neurotoxicity of oral bisacetatoamminedichlorohexylamine- platinum(IV) in comparison to cisplat- in and tetraplatin in the rat[J].Cancer Research,1994(54):629-631. |
| [10] | Mckeage M J;Kelland L R;Boxall F E et al.Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents[J].British Journal of Cancer,1993,617:936-1000. |
| [11] | Mckeage M J;Kelland L R;Boxall F E et al.Schedule dependency of orally administered bis-acetato-ammine- dichloro-cyclohexylamineplatinum(IV)(JM216) in vivo[J].Cancer Research,1994,54(15):4118-4122. |
| [12] | Mckeage M J;Morgan S E;Boxall F E et al.Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes:ammine/amine platinum(IV) dicarboxylates[J].Cancer Chemotherapy and Pharmacology,1994,33(06):497-503. |
| [13] | Raynand F I;Boxall F E;Phyllis Goddard et al.Metabolism protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products[J].Anticancer Research,1996,16:1857-1862. |
| [14] | Mckeage M J;Prakash Mistry;Janet Ward et al.A phase I and pharmacologystudy of an oral platinum complex JM216 dose-dependent pharmacokinetics with single-dose administration[J].Cancer Chemotherapy and Pharmacology,1995,36:451-458. |
| [15] | Mckeage M J;Raynaud F I;Ward J et al.Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer[J].Journal of Clinical Oncology,1997,15(07):2691-2700. |
| [16] | Beale,P;Raynaud,F;Hanwell,J;Berry,C;Moore,S;Odell,D;Judson,I .Phase I study of oral JM216 given twice daily.[J].Cancer Chemotherapy and Pharmacology,1998(2):142-148. |
| [17] | Groem H J M;Smit E F;Bauer J et al.[J].Proceedings of the American Society of Clinical Oncology,1996,437:1128. |
| [18] | Judson I R;Ceruy T;Pelbaum R E et al.Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer:an EORTC early clinical studies group investigation[J].Annals of Oncology,1997,8(06):604-606. |
上一张
下一张
上一张
下一张
计量
- 下载量()
- 访问量()
文章评分
- 您的评分：
-
10%
-
20%
-
30%
-
40%
-
50%